Avitide Finalizes Development of AVIPure®-COV2S, an Affinity Purification Resin for Covid-19 Vaccines

Avitide, Inc. the industry leader in the discovery and development of affinity purification chromatography resins, announced that it has finalized the development of an affinity bioprocess resin for the purification of recombinant COVID-19 vaccines. The AVIPure®-COV2S resin delivers outstanding performance as a capture resin for the majority of recombinant COVID-19 vaccines.

Read More

Allergan and Avitide Expand Partnership to Develop Custom Affinity Chromatography Technologies

Avitide Inc., the industry leader in the discovery and development of custom affinity purification resins, announce a partnership expansion with Allergan. Under the terms of the agreement, Avitide will use its proprietary affinity chromatography discovery, development, and supply platform for programs defined by Allergan.

Read More

Gemini Therapeutics and Avitide Enter Into Exclusive License Agreement

Avitide, Inc., the industry leader in the discovery and development of custom affinity purification resins, announces that it has entered into an exclusive license agreement to support the development of one of Gemini Therapeutics’ therapeutic programs.

Read More